Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).
暂无分享,去创建一个
N. Agarwal | J. Chakrabarti | K. Fizazi | J. Mateo | N. Shore | A. Azad | N. Matsubara | S. Lanzalone | A. Niyazov | Hsiang-Chun Chen | F. Saad